Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Michael Raab Biography and Net Worth

CEO of Ardelyx

President & Chief Executive OfficerMike has served as Ardelyx’s President and Chief Executive Officer since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA), one of the world’s largest and most successful venture capital firms, where he specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors.

Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. In this position, Mike launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of hyperphosphatemia, with over $1.0 billion in worldwide sales in 2013. Mike was also instrumental in the worldwide launch of Genzyme’s therapies for Gaucher disease, Ceredase and Cerezyme. Mike also spent two years with Genzyme’s diagnostic products and services division. Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers.

What is Michael Raab's net worth?: The estimated net worth of Michael Raab is at least $5.54 million as of December 10th, 2024. Mr. Raab owns 1,150,385 shares of Ardelyx stock worth more than $5,544,856 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Raab may own. Additionally, Mr. Raab receives an annual salary of $1,030,000.00 as CEO at Ardelyx. Learn More about Michael Raab's net worth.
How old is Michael Raab?: Mr. Raab is currently 59 years old. There are 6 older executives and no younger executives at Ardelyx. Learn More on Michael Raab's age.
What is Michael Raab's salary?: As the CEO of Ardelyx, Inc., Mr. Raab earns $1,030,000.00 per year. Learn More on Michael Raab's salary.
How do I contact Michael Raab?: The corporate mailing address for Mr. Raab and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Michael Raab's contact information.
Has Michael Raab been buying or selling shares of Ardelyx?: In the last ninety days, Michael Raab has sold $625,449.90 in Ardelyx stock. Most recently, Michael Raab sold 25,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $5.26, for a transaction totalling $131,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,150,385 shares of the company's stock, valued at $6,051,025.10. Learn More on Michael Raab's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, insiders at the biopharmaceutical company sold shares 42 times. They sold a total of 1,331,757 shares worth more than $9,236,457.25. The most recent insider tranaction occured on December, 10th when CEO Michael Raab sold 25,000 shares worth more than $131,500.00. Insiders at Ardelyx own 5.9% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 12/10/2024.

Michael Raab Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	25,000	$5.26	$131,500.00	1,150,385
11/25/2024	Sell	25,000	$5.38	$134,500.00	1,150,385
11/20/2024	Sell	31,980	$4.79	$153,184.20	1,175,385
11/11/2024	Sell	2,743	$4.90	$13,440.70	1,207,365
10/28/2024	Sell	25,000	$5.91	$147,750.00	1,210,108
10/11/2024	Sell	7,500	$6.01	$45,075.00	1,210,108
9/26/2024	Sell	3,000	$6.07	$18,210.00	1,217,608
9/11/2024	Sell	35,000	$5.61	$196,350.00	1,220,608
8/27/2024	Sell	7,500	$6.22	$46,650.00	1,219,509
8/20/2024	Sell	32,225	$5.86	$188,838.50	1,227,009
8/12/2024	Sell	1,229	$5.71	$7,017.59	1,259,234
7/29/2024	Sell	30,000	$5.64	$169,200.00	1,260,463
7/15/2024	Sell	7,500	$5.97	$44,775.00	1,260,463
6/28/2024	Sell	2,310	$6.59	$15,222.90	1,267,963
6/13/2024	Sell	35,000	$6.65	$232,750.00	1,270,273
5/29/2024	Sell	7,500	$6.72	$50,400.00	1,270,273
5/14/2024	Sell	3,000	$7.99	$23,970.00	1,307,933
4/29/2024	Sell	30,000	$6.40	$192,000.00	1,310,933
4/15/2024	Sell	7,500	$7.06	$52,950.00	1,310,933
4/1/2024	Sell	1,518	$7.31	$11,096.58	1,318,433
2/20/2024	Sell	22,917	$8.75	$200,523.75	1,319,951
11/20/2023	Sell	11,368	$4.36	$49,564.48	867,868
8/21/2023	Sell	11,419	$3.55	$40,537.45	876,236
5/23/2023	Sell	11,357	$3.65	$41,453.05	887,655
2/21/2023	Sell	13,449	$3.00	$40,347.00	896,012
8/22/2022	Sell	6,146	$0.98	$6,023.08	662,680
6/6/2022	Sell	103,624	$0.65	$67,355.60	668,826
5/20/2022	Sell	6,124	$0.67	$4,103.08	772,450
2/22/2022	Sell	6,229	$0.67	$4,173.43
11/22/2021	Sell	2,607	$0.99	$2,580.93
8/20/2021	Sell	2,573	$1.32	$3,396.36	329,730
5/20/2021	Sell	2,534	$7.09	$17,966.06	214,754
9/15/2020	Sell	106,337	$5.61	$596,550.57
7/2/2020	Sell	23,128	$7.01	$162,127.28
6/1/2020	Sell	23,128	$7.33	$169,528.24	208,057
5/4/2020	Sell	15,941	$7.01	$111,746.41	208,057
4/17/2020	Sell	9,428	$7.02	$66,184.56	208,057
4/15/2020	Sell	500	$7.03	$3,515.00	208,057
3/2/2020	Sell	11,123	$7.00	$77,861.00
2/5/2020	Sell	25,000	$7.32	$183,000.00
6/4/2019	Sell	10,054	$2.54	$25,537.16
1/2/2019	Sell	19,644	$1.70	$33,394.80
9/8/2015	Sell	9,785	$20.29	$198,537.65	1,518

Michael Raab Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $4.82

$4.58

$4.96

50 Day Range

MA: $5.45

$4.50

$6.49

2 Week Range

Now: $4.82

$4.32

$10.13

Volume

5,041,507 shs

Average Volume

4,893,465 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

Michael Raab Biography and Net Worth

What is Michael Raab's net worth?

How old is Michael Raab?

What is Michael Raab's salary?

How do I contact Michael Raab?

Has Michael Raab been buying or selling shares of Ardelyx?

Who are Ardelyx's active insiders?

Are insiders buying or selling shares of Ardelyx?